A corn cob type pet chew where the corn cob has improved digestibility. The improved digestibility is provided by digestive enzymes and/or incorporating selected locations of mechanical weaking so that the corn cob will also more readily reduce in size when chewed upon by the animal. The corn cob may also optionally include other additives, such as mineral fillers. The minerals may also assist in digestion.

A corn cob type pet chew where the corn cob has improved digestibility. The improved digestibility is provided by digestive enzymes and/or incorporating selected locations of mechanical weaking so that the corn cob will also more readily reduce in size when chewed upon by the animal. The corn cob may also optionally include other additives, such as mineral fillers. The minerals may also assist in digestion.

An in-feed life cycle interruption agent (LCIA) including a granulated core comprising LCIA material and a coating on the core. Related methods and products are also disclosed. Examples of LCIA include, but are not limited to Naturally occurring insect toxins (NOIT such as saponin and Insect Growth Regulators (IFR) such as Cyromazine.

Provided is a use of usnic acid or a salt of usnic acid or a formulation thereof in the preparation of anti-avian coccidiosis drugs or feed additives. Also provided are anti-avian coccidiosis drugs and feed additives comprising usnic acid or a salt of usnic acid or a formulation thereof. Both the use of usnic acid or a salt of usnic acid or a formulation thereof in the preparation of anti-avian coccidiosis drugs or feed additives and anti-avian coccidiosis drugs and feed additives comprising usnic acid or a salt of usnic acid or a formulation thereof provide a new way for treating and preventing avian coccidiosis. The addition of Usnea or usnic acid or a salt of usnic acid or a formulation thereof to feedstuff may realize effective anti-avian coccidiosis.

Disclosed is a method for preparing an attapulgite-based pH-responsive antibacterial material, including: directly spraying a natural aldehyde-based antibacterial agent onto an attapulgite powder under stirring, and constantly stirring the attapulgite powder for 20-30 min; grinding the attapulgite powder in a ball mill for 30-60 min to obtain a ground attapulgite powder; placing the ground attapulgite powder in a stirred tank, and spraying a chitosan-citric acid aqueous solution onto the ground attapulgite powder; after spraying, constantly stirring the ground attapulgite powder for 30-120 min; and finally drying the ground attapulgite powder to obtain a dried attapulgite powder, sieving the dried attapulgite powder to obtain a sieved attapulgite powder, and packaging the sieved attapulgite powder to obtain the antibacterial material.

Disclosed is a method for preparing an attapulgite-based pH-responsive antibacterial material, including: directly spraying a natural aldehyde-based antibacterial agent onto an attapulgite powder under stirring, and constantly stirring the attapulgite powder for 20-30 min; grinding the attapulgite powder in a ball mill for 30-60 min to obtain a ground attapulgite powder; placing the ground attapulgite powder in a stirred tank, and spraying a chitosan-citric acid aqueous solution onto the ground attapulgite powder; after spraying, constantly stirring the ground attapulgite powder for 30-120 min; and finally drying the ground attapulgite powder to obtain a dried attapulgite powder, sieving the dried attapulgite powder to obtain a sieved attapulgite powder, and packaging the sieved attapulgite powder to obtain the antibacterial material.

An agent for suppressing inflammation in the intestinal cell of a non-human animal comprises cashew nut shell liquid, heated cashew nut shell liquid, anacardic acid, cardanol, and/or cardol.

Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.

A nutritionally complete animal food including, vitamins, and minerals to sustain the animal's health and wellness. The one or more ingredients containing cannabinoids added to the nutritionally complete animal food at the time of manufacturing. These cannabinoids are selected from the group consisting of Cannabichromenic acid (CBCA), Cannabidiolic acid (CBDA), Cannabidivarinic acid (CBDVA), Cannabigerolic acid (CBGA), Cannabinolic acid (CBNA), Δ9-Tetrahydrocannabinolic acid (THCA), Tetrahydrocannabinolic acid (THCVA) and combinations thereof. The concentrations of each of the cannabinoids are each less than 100 parts per million (ppm) in the at least one ingredient. In an alternate embodiment, the one or more ingredients have cannabinoids include in an aggregate concentration of less than 100 parts per million (ppm).

A nutritionally complete animal food including, vitamins, and minerals to sustain the animal's health and wellness. The one or more ingredients containing cannabinoids added to the nutritionally complete animal food at the time of manufacturing. These cannabinoids are selected from the group consisting of Cannabichromenic acid (CBCA), Cannabidiolic acid (CBDA), Cannabidivarinic acid (CBDVA), Cannabigerolic acid (CBGA), Cannabinolic acid (CBNA), Δ9-Tetrahydrocannabinolic acid (THCA), Tetrahydrocannabinolic acid (THCVA) and combinations thereof. The concentrations of each of the cannabinoids are each less than 100 parts per million (ppm) in the at least one ingredient. In an alternate embodiment, the one or more ingredients have cannabinoids include in an aggregate concentration of less than 100 parts per million (ppm).